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Abstract
Numerous infectious diseases impacting livestock impose an important economic 
burden and in some cases also represent a threat to humans and are classified as zo-
onoses. Some zoonotic diseases are transmitted by vectors and, due to complex en-
vironmental and socio-economic factors, the distribution of many of these pathogens 
is changing, with increasing numbers being found in previously unaffected countries. 
Here, we developed a multiplex assay, based on a suspension microarray, able to 
detect specific antibodies to five important pathogens of livestock (three of them 
zoonotic) that are currently emerging in new geographical locations: Rift Valley fever 
virus (RVFV), Crimean-Congo haemorrhagic fever virus (CCHFV), Schmallenberg 
virus (SBV), Bluetongue virus (BTV) and the bacteria complex Mycobacterium tuber-
culosis. Using the Luminex platform, polystyrene microspheres were coated with re-
combinant proteins from each of the five pathogens. The mix of microspheres was 
used for the simultaneous detection of antibodies against the five corresponding dis-
eases affecting ruminants. The following panel of sera was included in the study: 50 
sera from sheep experimentally infected with RVFV, 74 sera from calves and lambs 
vaccinated with SBV, 26 sera from cattle vaccinated with Mycobacterium bovis, 30 
field sera from different species of ruminants infected with CCHFV and 88 calf sera 
infected with BTV. Finally, to determine its diagnostic specificity 220 field sera from 
Spanish farms free of the five diseases were assessed. All the sera were classified 
using commercial ELISAs specific for each disease, used in this study as the refer-
ence technique. The results showed the multiplex assay exhibited good performance 
characteristics with values of sensitivity ranging from 93% to 100% and of specific-
ity ranging from 96% to 99% depending on the pathogen. This new tool allows the 
simultaneous detection of antibodies against five important pathogens, reducing the 
volume of sample needed and the time of analysis where these pathogens are usually 
tested individually.
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1  | INTRODUC TION
Infectious diseases account for more than 20% of the overall 
losses in livestock production worldwide, with important con-
sequences for food security and health of both animals and hu-
mans. Many of these pathogens are vector-borne diseases, which 
have a zoonotic character, with serious impact in both animal and 
public health. Environmental and socio-economic changes, such 
as global warming, changes in land use, host migration and glo-
balization, have influenced the distribution of those infectious 
diseases transmitted by vectors, increasing their potential to 
spread to previously unaffected regions (Bett et al., 2017; Brand 
& Keeling, 2017; Dash, Bhatia, Sunyoto, & Mourya, 2013; Weaver 
& Reisen, 2010). This is the case for pathogens such as Crimean-
Congo haemorrhagic fever virus (CCHFV), Rift Valley fever virus 
(RVFV), Schmallenberg virus (SBV), Bluetongue virus (BTV) or 
the bacteria complex Mycobacterium tuberculosis (Estrada-Peña, 
Ruiz-Fons, Acevedo, Gortazar, & de la Fuente, 2013; Maltezou 
& Papa, 2010; Rolin, Berrang-Ford, & Kulkarni, 2013; Samy & 
Peterson, 2016). Moreover these viruses, with the exception of 
SBV, as well as the bacteria complex Mycobacterium tuberculosis 
are listed as notifiable pathogens by the OIE (World Organization 
for Animal Health) and thus, their identification is crucial to dis-
ease management (OIE, 2020). Taken together, these factors are 
necessary for better preparedness, surveillance and control of 
these and other pathogens, in order to reduce the social and eco-
nomic consequences of these diseases.
The panel of pathogens for this study include three viruses of 
the Bunyavirales order, namely CCHFV, RVFV and SBV. CCHFV is 
one of the most widespread tick-borne zoonotic viruses (Bente 
et al., 2013) and while causing an asymptomatic infection in in-
fected animals (domestic and wild ruminants), it can cause severe 
haemorrhagic fever in humans, resulting in high case fatality rates. 
More recently, some human cases have been reported for the 
first time in South-Eastern Europe (Mertens, Schmidt, Ozkul, & 
Groschup, 2013) and Spain (Negredo et al., 2019). The transmission 
to humans occurs through tick bites or exposure to blood or other 
body fluids of an infected animal or human (Bente et al., 2013). 
RVFV is a mosquito-borne virus infecting both livestock and humans 
(Wright, Kortekaas, Bowden, & Warimwe, 2019) with infections 
causing a high rate of abortions in pregnant domestic ruminants, 
and high mortality rates among newborns, causing devastating so-
cio-economic impacts (Sindato, Karimuribo, & Mboera, 2012). In 
addition, numerous outbreaks have been reported in humans es-
pecially in Africa and Middle East countries (Aradaib et al., 2013; 
Hassan, Ahlm, Sang, & Evander, 2011; Himeidan, Kweka, Mahgoub, 
El Rayah, & Ouma, 2014). Although not yet detected in Europe, 
RVFV introduction is a real concern due to the presence of compe-
tent arthropod vectors (Brustolin et al., 2017).
SBV and BTV, the later belonging to the Reoviridae family 
of RNA viruses, are among the most important pathogens af-
fecting different species of ruminants such as cattle, goats and 
sheep (Rojas, Rodríguez-Martín, Martín, & Sevilla, 2019; Wernike 
& Beer, 2017). Biting midges are the main vector involved in the 
transmission of these two viruses. Clinical signs associated with 
SBV are typically non-specific in adult cattle (such as fever, re-
duced milk yield, diahrrea) and rare in adult sheep and goat, but 
infection of pregnant females is associated with congenital mal-
formations and stillbirths (Hoffmann et al., 2012). For BTV, infec-
tion in adult cattle and goat is generally subclinical but is more 
prounonced in adult sheep (such as fever, congestion of nasal and 
oral mucosa and can cause hemorrhages in the nose, lips, and 
tongue that can result in death) and infection of pregnant sheep 
can be associated with congenital malformations and stillbirths 
(Rojas et al., 2019). Outbreaks of these two diseases have signifi-
cant economic impact, due to loss of productivity and restrictions 
of animal movement and trade (Häsler, Alarcon, Raboisson, Waret-
Szkuta, & Rushton, 2015; Rushton & Lyons, 2015).
Mycobacterium bovis, a member of the M. tuberculosis complex, 
is a highly pathogenic mycobacterium that causes disease mainly 
in cattle, but also in other species of ruminants and poses a high 
zoonotic risk due to possible transmission to humans which usually 
occurs after close contact with infected animals or consumption 
of unpasteurized and contaminated dairy products (El-Sayed, El-
Shannat, Kamel, Castañeda-Vazquez, & Castañeda-Vazquez, 2016; 
Mathema, Kurepina, Bifani, & Kreiswirth, 2006). The disease has an 
impact on productivity of animals and consequently is linked to eco-
nomic losses (Ejeh et al., 2014).
In the present work, we describe the development of a multiplex 
serological assay for the simultaneous detection of antibodies in ru-
minant serum, against CCHFV, RVFV, SBV, BTV and M. bovis for sur-
veillance purposes. The nucleocapsid (N) protein of CCHFV, RVFV 
and SBV was selected as target antigens (Bente et al., 2013; Fafetine 
et al., 2007; Walter & Barr, 2011). For BTV, the viral protein, VP7, one 
of the two major structural proteins of the BTV core, was chosen 
(Wade-Evans et al., 1996). Finally, the MPB83 of M. bovis, which is 
one of the two major antigens highly expressed by M. bovis, was used 
as target antigen (Wiker, 2009).
Initially, to set up this multiplex test, several panels of sera from 
ruminants (cattle, goat and sheep) experimentally infected with the 
different pathogens, or serum from field animals, were used. To 
determine the diagnostic specificity of the test, a total of 220 sera 
from Spanish farms free of these five diseases were included in the 
studies. All the sera were previously characterized by individual en-
zyme-linked immunosorbent assays (ELISAs) specific for each patho-
gen and considered in this study as our reference technique.
This new approach could be used as a high throughput screen-
ing tool to assess the presence and prevalence of antibodies 
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against 5 different highly pathogenic agents and identify regions 
at risk of infection. Moreover, these pathogens are often reported 
in ruminant populations which can cause huge economic losses to 
farmers in developing countries. These infections can routinely be 
detected using serological or microbiological methods which can 
be reinforced or replaced by multiplex assays, where detection of 
different pathogens is done in a single reaction. In addition, simul-
taneous testing of these pathogens reduces the volume of sample 
needed compared to performing the different ELISAs. This infor-
mation will help to minimize the spread and further transmission 
of those pathogens within the human population.
2  | MATERIAL S AND METHODS
2.1 | Recombinant proteins
cDNAs designed to express the full length nucleoproteins of 
CCHFV Baghdad 12 strain (GenBank accession CAD61342.1, but 
with conservative substitutions T111I, R195H and H445D) and 
RVFV (GenBank accession X53771.1) were generated synthetically 
(Genewiz). cDNA of the nucleoprotein of SBV (GenBank accession 
AGC93538) was available at INGENASA. The three sequences 
were cloned into the pET-28a-6His-SUMO plasmid (Thermo 
Fisher Scientific) for bacterial expression of corresponding fu-
sion proteins with the small ubiquitin-like modifier (SUMO) and 
6× histidine-tag at their amino termini. Resulting plasmids were 
verified by sequence analysis and transformed into Escherichia 
coli BL21 (DE3) Rosetta2 (Novagen). The recombinant proteins 
were purified using Ni-NTA affinity chromatography followed by 
size exclusion chromatography as described by Carter, Barr, and 
Edwards (2012). Briefly, the expression of the three N proteins 
was induced with 500 μM isopropyl-β-d-thiogalactoside overnight 
(o/n) at 18°C. The cells were harvested by centrifugation and lysed 
with lysozyme (1 mg/ml) and sonication. The soluble fraction was 
separated from the cell debris by centrifugation, after which the 
6×His-SUMO-N proteins were purified from the soluble fraction 
using Ni-NTA resin (ABT) and eluted with increasing concentra-
tions of imidazole. The purified fusion proteins were cleaved o/n 
using SUMO protease (produced in-house at the University of 
Leeds), and the 6× histidine and SUMO tags were removed using 
a second nickel column, followed by a final size exclusion chroma-
tography step with a HiLoad® 26/600 Superdex® 75 pg column 
(GE Healthcare) using an Akta prime (GE Healthcare).
The VP7 of BTV serotype 10 (GenBank accession No. 
YP_052967) was produced in insect cells from a recombinant bac-
ulovirus already available in the laboratory. Briefly, Sf9 insect cells 
(from Spodoptera frugiperda) were cultured in complete Grace´s 
medium and infected with the corresponding recombinant bacu-
lovirus. The cells were lysed and the VP7 was purified from the 
soluble fraction by affinity chromatography using a specific mono-
clonal antibody (MAb) to BTV VP7 (INGENASA). The glutathione 
S-transferase (GST)-tagged MPB83 was expressed in insect cells 
and was already available in the laboratory (Fresco-Taboada et al., 
2019). Briefly, Sf9 cells were grown in Sf-900™ II SFM (Thermo 
Fisher Scientific) without serum and infected with the recombi-
nant baculovirus containing the MPB83-GST gene. The cells were 
then centrifuged and the MPB83-GST was purified from the cul-
ture medium by affinity chromatography with GST Gravitrap™ (GE 
Healthcare) according to the manufacturer's instructions.
Protein gel electrophoresis followed by Coomassie staining 
was used to assess the purity and molecular size of each protein. 
The proteins were transferred to nitrocellulose membrane and 
Western blot analysis was performed using specific MAbs to each 
of the target proteins (1F8 for RVFV N protein, 1D5D12 for SBV 
N protein, 83CA3 for MPB83-GST, 2G10 for CCHFV N protein, 
and 2D7 for BTV VP7, all produced at INGENASA) to confirm their 
immunogenicity.
2.2 | Production and characterization of the 
monoclonal antibodies
The animal research was approved by the Consejería de Medio 
Ambiente, Administración Local y Ordenación del Territorio 
(Department of Environment, Local Administration and Territorial 
Planning) from the Comunidad de Madrid (Community of Madrid, 
Spain) reference PROEX nº024/18.
Female BALB/c mice aged from 9 to 12 weeks, weight range from 
20 g to 40 g were housed in temperature-controlled, pathogen-free 
rooms with access to pelleted food and water ad libitum. The mice 
were maintained under standard animal housing conditions in an 
authorized centre (INGENASA, Community of Madrid registration 
number ES280790000095). Originally, the mice were commercially 
obtained from Harlan Interfauna Ibérica (Spain) and are now bred 
internally by the Animal Department of INGENASA.
The mice (4 per group, one group per antigen) were injected 
intraperitoneally (IP) with the purified RVFV NP and CCHFV NP 
produced in E. coli. For the first immunization, 25 µg of antigen emul-
sified in complete Freund's adjuvant (Sigma-Aldrich) was used. For 
the following seven immunizations (one every 2 weeks), the antigen 
was emulsified in incomplete Freund's adjuvant (Sigma-Aldrich). 
As a control, one mouse was immunized with phosphate-buffered 
saline (PBS) instead of antigen. Mice were bled by the tail 7 days 
after each immunization to detect the antibody titre in serum. Mice 
sera were obtained by allowing the blood to coagulate for 30 min 
at room temperature (RT) and further centrifugation at 1,500 g for 
10 min at 4°C. The antibody titre was checked by indirect ELISA 
with the CCHFV N and RVFV N proteins. Previously to obtaining 
the hybridomas, three immunizations on three consecutive days 
were done with antigen emulsified in PBS.
The mice were euthanized by inhalation of CO2 and their spleen 
was collected. To obtain hybridomas producing specific MAbs, fu-
sions were done between the B cells of the mice spleen and NP3 my-
eloma cells (Sanz, García-Barreno, Nogal, Viñuela, & Enjuanes, 1985). 
The supernatants of hybridoma clones were screened by indirect 
4  |     HOSTE ET al.
ELISA with the corresponding N protein and a negative antigen (the 
N protein of CCHFV for the hybridomas producing MAbs to RVFV N 
protein and vice versa) and were subsequently subcloned to obtain 
single hybridoma producing a specific monoclonal antibody. The su-
pernatants of hybridoma containing the monoclonal antibodies were 
further purified using rprotein A/protein G GraviTrap columns (GE 
Healthcare) following the manufacturer's instructions. After assess-
ing the purity of each monoclonal antibody by gel electrophoresis, 
the MAbs were further labelled with peroxidase according to the 
method described by Nakane and Kawaoi (1974). The specificities 
of the MAbs were determined by indirect ELISA and Western blot 
analysis using the corresponding recombinant N protein as antigen. 
The isotypes of the MAbs were determined by ELISA, using specific 
anti-mouse subtype antisera (Sigma). A competition ELISA between 
the different MAbs was performed in order to detect whether they 
mapped in the same or different antigenic areas.
Monoclonal antibodies against the N protein of SBV, the VP7 of 
BTV and the MPB83 of M. bovis were already available in INGENASA 
and produced the same way as the MAbs against the N proteins of 
CCHFV and RVFV.
2.3 | Serum samples
In this study, the panel of serum samples consisted of 334 positive 
sera including experimental and positive field samples and 220 neg-
ative field sera. For the detection of antibodies to RVFV, 56 serum 
samples from sheep experimentally inoculated with RVFV were pro-
vided by INIA-CISA, some of them previously characterized (Lorenzo, 
López-Gil, Ortego, & Brun, 2018; Lorenzo, López-Gil, Warimwe, & 
Brun, 2015). For detection of antibodies to SBV, 33 serum samples 
from calves and 41 serum samples from lambs experimentally in-
fected with SBV were available at INGENASA, from a previous in-
ternal project. For the detection of antibodies to M. bovis, 29 serum 
samples from cattle vaccinated intramuscularly with M. bovis were 
available at INGENASA, from the European project WildTBVac (Call 
Identifier: FP7-KBBE-2013-7; Grant agreement nº 613799). For de-
tection of antibodies to CCHFV, 16 field serum samples from cattle, 
10 from sheep and 4 from goats naturally infected by CCHFV were 
provided by the Faculty of Veterinary Medicine in Skopje (USCM, 
North Macedonia). For the detection of antibodies to BTV, 73 serum 
samples from cattle experimentally infected with BTV were avail-
able at INGENASA, obtained from previous projects (PROFIT, Ref. 
CIT-010000-2005-81 and Comunidad de Madrid, Ref. 27/2007) and 
15 serum samples from SBV infected animals, also positive to BTV. 
Finally, a collection of 220 negative field samples (87 from cattle, 67 
from goats and 66 from sheep) from Spanish farms were evaluated.
2.4 | Coupling of target antigens to beads
The coupling of antigens to beads was described recently by Aira 
et al. (2019). Briefly, the five target proteins were covalently coupled 
to five different regions (regions #12, #18, #21, #25 and #30) of car-
boxylated magnetic microspheres (Luminex) using the xMAP® Cookbook 
by Angeloni et al. (2016). Briefly, 1 × 106 microspheres, identified indi-
vidually by a unique fluorescence ratio, were activated by addition of 
sulpho-N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride), which is based on a two-step carbodiim-
ide reaction (Hermanson, 2013). Once activated, the beads were incu-
bated with different amounts of the corresponding protein ranging from 
12.5 μg to 50 μg per one million beads in a final incubation volume of 
500 μl, and incubated for 2 hr with rotation in dark. RVFV N protein was 
coupled to region #12, SBV N protein to region #18, MPB83-GST to 
region #21, CCHFV N protein to region #25 and BTV VP7 to region #30. 
After washing, the beads were resuspended in 1 ml of storage buffer 
(PBS with 1% bovine serum albumin (BSA) and 0.05% azide) and were 
kept in the dark at 4°C. The concentration of the beads was determined 
by counting on a Neubauer plate.
Serial dilutions of monoclonal antibodies specific to each protein 
were used to perform a confirmation assay, in order to assess the 
coupling efficiency. All the MAbs were produced at INGENASA: 1F8 
for RVFV N protein, 1D5D12 for SBV N protein, 83CA3 for MPB83-
GST, 2G10 for CCHFV N protein and 2D7 for BTV VP7.
2.5 | Bead-based assay for antibody detection in 
ruminant sera
The five respective antigen-coupled microspheres were resus-
pended by vortex and sonication in order to perform the five-plex 
assay. A mix of beads was prepared mixing the five bead regions 
in assay buffer (PBS with 1% BSA) to a final concentration of 25 
beads/µL for each bead region. As the beads are light-sensitive, 
they were protected from the light. To 50 µl of individual ruminants' 
serum samples, diluted at 1/100 in assay buffer, was added 50 µl 
of the bead mixture. This mix was incubated for 1 hr at RT and 
650 rpm in a mini-shaker PSU-2T (Biosan). Ninety-six-well plates 
(Stripwell™ Microplate Medium binding Polystyrene, CoStar), pre-
viously blocked for 30 min with StabilZyme® SELECT Stabilizer 
(Surmodics), were used for the assay. After every incubation step, 
a magnetic plate separator (Luminex) was used to wash the plate 
twice with washing buffer (PBS with 1% BSA and 0.05% Tween 20). 
Then, 50 µl of the monoclonal anti-ruminant antibody EG5 labelled 
with biotin (INGENASA) was added to each well, at a final concen-
tration of 0.5 µg/ml in assay buffer, for 1 hr at RT and 650 rpm. Next, 
50 µl of Streptavidin R-phycoerythrin (Life Technologies) at 2 µg/ml 
in assay buffer were added per well and incubated for 30 min at RT 
and 650 rpm. Finally, the beads were washed twice with washing 
buffer and resuspended in 100 µl/well of washing buffer. The results 
were read out using MAGPIX® reader (Luminex). To be measured, 
the median fluorescence intensity (MFI) had to count a minimum of 
50 events of each bead region.
One well per assay was incubated with GIBCO™ foetal bovine 
serum (Thermo Fisher Scientific) as background signal. ELISA-
confirmed positive sera to each antigen, used as positive controls 
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for the targeted bead region and negative controls for the other 
beads, were included in every plate to assess the performance of 
the test.
2.6 | Data processing and statistical analysis
To statistically analyse the data obtained, the MedCalc® 10 soft-
ware was used. Receiver operating characteristic (ROC) curves 
analysis were made to establish the optimal cut-off value for each 
bead region. Prior to the analyses, the samples were classified 
into positive or negative based on five commercial ELISAs which 
were used as the reference techniques in this study: INGEZIM 
Schmallenberg Compac 2.0 (13.SBV.K3, INGENASA) for detection 
of specific antibodies against SBV, INGEZIM BTV Compac 2.0 (12.
BTV.K3, INGENASA) for detection of specific antibodies against 
BTV, INGEZIM Tuberculosis DR (10.TB*.K0, INGENASA) for detec-
tion of specific antibodies against M. bovis, ID Screen® Rift Valley 
Fever Competition Multi-species (IDvet) for detection of specific 
antibodies against RVFV and ID Screen® CCHF Double Antigen 
Multi-species (IDvet) for detection of specific antibodies against 
CCHFV. To measure the inter-rater reliability between the refer-
ence ELISAs and the bead-based assay, Cohen’s kappa coefficient 
was calculated.
3  | RESULTS
3.1 | Production of the target antigens of the 
different pathogens
Recombinant viral proteins were prodecued in different expression 
systems, as described in M& M section. A summary of the differ-
ent target antigens is shown in Table 1. The expression and puri-
fication of the proteins was followed by gel electrophoresis and 
Coomassie blue staining, revealing the recombinant proteins with 
the expected molecular weights of 54 kDa, 27.4 kDa, 26.2 kDa, 
38.5 kDa and 46.3 kDa for CCHFV N protein, RVFV N protein, SBV 
N protein, VP7 of BTV and the MPB83-GST of M. bovis, respec-
tively (Figure 1, lane 1–5). A faint band probably corresponding to 
a degradation product of the BTV VP7 (approximately 28 kDa) and 
a faint band corresponding to the size of the GST (26 kDa) were 
observed in lanes 4 and 5, respectively. Western blot analysis using 
specific MAbs to each of the target proteins was performed to con-
firm their immunogenicity. A specific band corresponding to each 
antigenic protein was observed, while neither of the faint bands 
observed in Figure 1 (lanes 4 and 5) were observed in the Western 
blot (data not shown).
3.2 | Production and characterization of the 
monoclonal antibodies
As described in Materials and Methods, monoclonal antibodies to 
CCHFV N protein and to RVFV N protein were produced and charac-
terized. Three MAbs against CCHFV N protein and 4 MAbs against 
RVFV N protein were obtained. The MAbs obtained reacted specifi-
cally with the N proteins of CCHFV and RVFV as expected, with no 
detectable cross-reaction with the other N protein. Finally, a compe-
tition ELISA between the MAbs was performed to identify whether 
they mapped in the same or in different antigenic areas. A summary 
of the characterization of the MAbs for CCHFV and RVFV is shown 
in Table 2.
TA B L E  1   Summary of the antigens used in the multiplex assay
Family Virus/Bacteria
Target 
antigen
Expected molecular 
weight (kDa)
Expression 
system Vector
Nairoviridae Crimean-Congo haemorrhagic 
fever virus
N protein 54 E. coli pET-28a-6His-SUMO
Phenuiviridae Rift Valley fever virus N protein 27.2 E. coli pET-28a-6His-SUMO
Peribunyaviridae Schmallenberg virus N protein 26 E. coli pET-28a-6His-SUMO
Reoviridae Bluetongue virus VP7 38.5 BES pAcYM1
Mycobacteriaceae Mycobacterium bovis MPB83-GST 46.3 BES pAcSECG2T
F I G U R E  1   Coomassie Blue staining of the five purified proteins 
used in the multiplex assay. From left to right: CCHFV N protein 
(lane 1, MW: 54 kDa), RVFV N protein (lane 2, MW: 27.2 kDa), SBV 
N protein (lane 3, MW: 26 kDa), BTV VP7 (lane 4, MW: 38.5 kDa) 
and MPB83-GST (lane 5, MW: 46.3 kDa)
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Monoclonal antibodies against the N protein of SBV, the VP7 of 
BTV and the MPB83 of M. bovis were already available in INGENASA 
and produced the same way as the MAbs against the N proteins of 
CCHFV and RVFV and characterized in previous work (not shown).
3.3 | Development and optimization of the 
multiplex assay
Firstly, the optimization of the coupling concentration of each anti-
gen to each bead region was determined individually with the spe-
cific monoclonal antibodies produced as described in Materials and 
Methods (data not shown). The optimal protein coupling concen-
tration was established as the highest MFI obtained with the mini-
mum amount of protein. The following quantities were used to coat 
1 × 106 beads for each bead region: 25 μg of RVFV N protein (region 
#12), 25 μg of SBV N protein (region #18), 25 µg of MPB83-GST (re-
gion #21), 25 μg of CCHFV N protein (region #25) and 50 μg of BTV 
VP7 (region #30).
Well-characterized serum samples for each pathogen were used 
to establish the optimal assay conditions for the screening. A mix 
of the 5 bead regions coupled to the target antigens was incubated 
with serial dilutions of specific reference serum samples against each 
pathogen and the assay was performed as described in Materials and 
TA B L E  2   Summary of the characterization of the MAbs anti-CCHFV N protein and anti-RVFV N protein
Name Class
Reactivity in 
western blot
Competition for the same antigenic area
3G7 2G10 1D6 1E9 1F8 2B12 2D10
MAb anti-CCHFV N 
protein
3G7 IgG1 +++
2G10 IgG1 +++
1D6 IgG1 +++
MAb anti-RVFV N protein 1E9 IgG1 +
1F8 IgG1 +++
2B12 IgG1 ++
2D10 IgG1 +++
F I G U R E  2   Determination of the 
screening conditions for the bead-
based assay. The median fluorescence 
intensity (MFI) for each bead region is 
given for different serum dilutions of one 
experimental reference serum. (a) RVFV 
experimental serum; (b) SBV experimental 
serum; (c) TB experimental serum; (d) 
CCHFV field positive serum; (e) BTV 
experimental serum; (f) foetal bovine 
serum
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Methods. The same pattern of results was obtained for each, with 
an increase in the MFI until a serum dilution of 1:200 or 1:400, and 
then a decrease in the signal detected, without any signal for the 
other beads (Figure 2a-e). Neither of the specific samples for each 
disease gave cross-reactivity with any of the other bead regions, cor-
responding to the other pathogens. Finally, the foetal bovine serum 
used as background for the different infectious agents did not show 
any reactivity with any of the five beads (Figure 2f). For screening 
purposes a dilution of the serum at 1:200 was selected (correspond-
ing to a sample volume of 0.5 μL), since this was the dilution showing 
the highest signal to most of the five beads regions, with no cross-re-
activity with the non-targeted antigens.
3.4 | Multiplex assay validation using 
experimental and field serum samples
After establishing the screening conditions, a collection of 554 rumi-
nants’ serum samplesfrom cattle, goats and sheep, previously classi-
fied as positive and negative by the ELISAs used as reference, were 
tested in the five-plex assay. A total of 56 RVFV experimental serum 
samples (50 positives and 6 negatives), 88 SBV experimental serum 
samples (74 positives and 14 negatives), 72 M. bovis experimental 
serum samples (26 positives and 46 negatives), 30 CCHFV field posi-
tive serum samples, 88 BTV experimental serum samples (73 positives 
from experimentally infected cattle and 15 positives from the SBV ex-
perimental sera) and 220 field serum samples from ruminants were 
included in this study. Out of the 220 field sera, all were classified as 
negative for RVFV and CCHFV. Twelve cattle sera, 1 sheep serum and 
23 goat sera were classified as positive for SBV and 13 cow sera were 
classified as positive for BTV. Finally, out of these 220 field sera, the 
sheep and goats’ sera were assayed in the INGEZIM Tuberculosis DR, 
according to the manufacturer’s instructions, and 3 were classified as 
positive for M. bovis (1 sheep and 2 goats). The serum sample volume 
needed to perform the five ELISAs used as references was 144 µL per 
animal. A summary of this classification is shown in Table 3.
After this classification, the complete panel of 554 ruminant 
serum samples were assayed in the five-plex assay and the results 
were statistically analysed by comparison with the results obtained 
with the reference techniques. Thus, a cut-off value was determined 
for each antigen using the MedCalc software. Based on these cut-
offs, the performance characteristics of the multiplex assay for each 
pathogen was determined.
The sensitivity values ranged from 93.1% for TB and BTV to 100% 
for CCHFV, and the specificity ranged from 96% for SBV to 99.4% 
for TB. For RVFV, most of the positive experimental sera gave a high 
MFI for its corresponding bead and out of the 220 negative field 
samples and the 6 negative experimental samples, 96.9% (219/226) 
were detected as true negatives (Figure 3a). Concerning SBV, all the 
experimental sera were true positive and 96% of the negative field 
samples (190/198) were classified as true negatives (Figure 3b). With 
regard to TB, the 26 experimental sera were considered true posi-
tive with one positive field sample (1/3) considered as true positive 
(Figure 3c). Moreover, 99.4% of the negative field samples (175/176) 
were classified as true negatives. Regarding CCHFV, all the positive 
field sera were true positives and 2.3% of the negative field samples 
(5/220) were considered false positive (Figure 3d). Finally, regard-
ing BTV, all the experimental sera were true positive (Figure 3e) and 
99.0% of the negative field samples were true negatives (205/207). 
These results are summarized in Table 4.
Finally, some of the positive experimental sera tested in the 
five-plex showed some reactivity with other bead regions than 
the targeted one: 8 RVFV experimental sera, 39 SBV experimental 
samples, 24 CCHFV positive field sera and 22 BTV experimental 
sera (Table 5).
3.5 | Statistical analysis
Using the Medcalc software, Cohen’s kappa coefficient was calcu-
lated to examine the agreement between the results obtained in the 
ELISAs and in the multiplex assay. For SBV, κ = 0.894 with a 95% 
confidence interval [0.842;0.946]. Cohen’s kappa coefficients were 
ranging from 0.894 for SBV to 0.939 for TB, corresponding to an al-
most perfect agreement between the ELISAs used as reference and 
the multiplex assay.
TA B L E  3   Serum classification with the ELISAs used as reference techniques for the different antigens
Reference 
technique
RVFV SBV TB CCHFV BTV
ID Screen® RVF 
Competition Multi-
species (IDvet)
INGEZIM 
Schmallenberg 
Compac 2.0 (13.
SBV.K3)
INGEZIM 
Tuberculosis 
DR (10.TB*.
K0)
ID Screen® CCHF 
Double Antigen 
Multi-species 
(IDVet)
INGEZIM BTV 
Compac 2.0 (12.
BTV.K3)
Experimental 
samples
Positive in ELISA 50 74 26 0 88
Negative in ELISA 6 14 46 0 0
Total number of experimental 
samples
56 88 72 0 88
Field samples Positive in ELISA 0 36 3 30 13
Negative in ELISA 220 184 133 220 207
Total number of field samples 220 220 136 250 220
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4  | DISCUSSION
Multiplex assays, which allow the detection of different pathogens 
in a single reaction, could replace individual assays routinely car-
ried out for the detection of these pathogens. Moreover, these as-
says reduce time, labor and sample volume requirements, allowing 
the testing of many samples for multiple targets simultaneously. 
This would greatly help in surveillance studies, by allowing the 
development of one unique plan for a complex infectious dis-
ease panel. This could be the case of diseases affecting livestock, 
especially in cases of zoonoses (such as CCHFV, RVFV and M. 
bovis), to control the distribution of the corresponding pathogens 
and prevent future outbreaks. This surveillance is also crucial for 
vector-borne diseases such as CCHFV, RVFV, BTV and SBV which 
F I G U R E  3   Validation of the bead-bead 
assay. Dot plot diagrams where each dot 
represents an individual sample: results 
obtained for RVFV N protein coupled to 
bead #12 (a), SBV N protein coupled to 
bead #18 (b), MPB83-GST coupled to 
bead #21 (c), CCHFV N protein coupled 
to bead #25 (d) and BTV VP7 coupled 
to bead #30 (e). The horizontal solid line 
corresponds to the cut-off values in each 
assay, according to the MedCalc software. 
X-axis shows the positive (1) or negative 
(0) classification of samples according to 
the ELISA used as reference technique 
in this study and Y-axis shows Median 
Fluorescence Intensity (MFI) obtained in 
the developed assay
TA B L E  4   Correlation between the bead-based assay and the ELISAs used as reference for the different antigens
Diagnosis in the five-plex RVFV SBV TB CCHFV BTV
True positive 50 103 27 30 94
False positive 7 8 1 5 2
True negative 217 190 175 215 205
False negative 2 7 2 0 7
Total 276 308 205 250 308
Cut-off (Median 
Fluorescence Intensity)
2,917 1,211 703 1,478 845,5
Sensitivity
[95% confidence interval]
96%
[86.3%–99.4%]
93.6%
[87.3%–97.4%]
93.1%
[77.2%–99%]
100%
[88.3%–100%]
93.1%
[86.2%–97.2%]
Specificity
[95% confidence interval]
96.9%
[93.7%–98.7%]
96.0%
[92.2%–98.2%]
99.4%
[96.9%–99.9%]
97.7%
[94.8%–99.2%]
99.0%
[96.5%–99.9%]
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already have competent vectors in regions or countries where the 
infectious agents have not yet reached (Estrada-Peña, Sánchez, & 
Estrada-Sánchez, 2012; Medlock & Leach, 2015; Rolin et al., 2013; 
Sanders et al., 2019). In this study, a five-plex assay has been de-
veloped and optimized to detect antibodies against the N protein 
of RVFV, SBV and CCHFV, and against the VP7 of BTV and MPB83 
of Mycobacterium bovis based on the Luminex platform. The mul-
tiplex assay was shown to have an almost perfect agreement with 
the ELISAs used as reference. Indeed, Cohen’s kappa coefficients 
all had a values close to 1. To increase the robustness of the diag-
nostic sensitivity and specificity of the assay, more positive and 
negative field sera should be tested.
The ELISAs used as reference techniques were either competi-
tion ELISAs (for the detection of antibodies to RVFV, SBV and BTV) 
or double antigen sandwich ELISAs (for the detection of antibodies 
to CCHFV and TB), which can detect both immunoglobulins G (IgG) 
and immunoglobulins M. Our multiplex assay uses an anti-ruminants' 
IgG, and thus, it can only detect IgG. That could explain some of the 
false-negative results, as some of the samples could have been taken 
at early days post-infection or post-vaccination, giving a high signal in 
the ELISAs, but being negatives in the multiplex. The confirmation of 
these results would actually raise the sensitivity of our multiplex assay.
Regarding TB, BTV and CCHFV, the few false-positive samples 
(1, 2 and 5 serum samples, respectively) come from ELISA-negative 
field samples and are clustered close to the cut-off of our multiplex 
assay. The false-positive sample for TB was close to the cut-off (op-
tical density450nm = 0.32) in the reference ELISA (negative if the opti-
cal density450nm < 0.37). The two false positives for BTV (MFI = 924 
and 1,005) are close to the cut-off established by MedCalc (negative 
if MFI < 845.5). Finally, out of the 5 false positives for CCHFV, two 
are strongly positive to SBV.
This last result raises the question of cross-reactivity of our assay. 
Due to sample volume constraints, not all the cross-reactive samples 
were assessed in other reference techniques to check the cross-re-
activity. A total of 8 RVFV experimental sera, 39 SBV experimental 
samples, 24 CCHFV positive field sera and 22 BTV experimental 
sera gave some positive results with other bead regions than the one 
it was intended for (see Table 5). Out of the 6 RVFV experimental 
sera positive to BTV, three were infected with BTV-4 (personal com-
munication) and the other three sera come from sheep from Spanish 
farms where the sheep could have been vaccinated against BTV as 
there is a ongoing BTV vaccination program in Spain or infected by 
BTV as it is endemic in certain parts of Spain (European Commission, 
2020). The 16 SBV experimental sera giving a signal above the cut-
off for CCHFV (ranging between 1,488.5 and 4,568) were tested and 
found to be negative in the reference CCHFV ELISA. For the BTV 
experimental sera, 20 sera gave a positive signal, but they were all 
close to the cut-off with MFI ranging between 735 and 1,469. As all 
these sera were from cows they could not be tested in the TB ELISA 
used as reference technique to validate or invalidate these results. 
For the CCHFV field positive sera, 16 sera gave MFI values above 
the SBV cut-off, between 1,304.5 and 8,863 and 7 of these were 
positive in the SBV reference ELISA. Some cross-reactivity could be 
expected between the CCHFV, RVFV and SBV beads as these three 
viruses belong to the Bunyavirales order, although each are classified 
within different family taxa, emphasizing their distant genetic relat-
edness. The N proteins of bunyavirales members are very immuno-
genic, easy to produce, well conserved within each viral species and 
the N proteins of CCHFV and RVFV were already used in multiplex 
assays (van der Wal et al., 2012; Wu et al., 2014). The use of other 
immunogenic proteins of these viruses such as the glycoproteins 
could overcome this issue (van der Wal et al., 2012).
A multiplex assay has already been developed with the Luminex 
platform to detect antibodies against RVFV and CCHFV but the 
proteins used to coat the bead regions were produced from vi-
ruses propagated in biosafety level (BSL)-3 or BSL-4 laboratories 
(O'Hearn et al., 2016). Here we describe a five-plex assay using 
recombinant proteins, produced in a BSL-2 laboratory, thus avoid-
ing the need of high-level containment facilities to develop such 
an assay.
TA B L E  5   Cross-reactivity between the positive experimental and field sera with the four other bead regions
Cross-reactive with other bead regions
Bead #12
RVFV N protein
Bead #18
SBV N protein
Bead #21
TB MPB83-GST
Bead #25
CCHFV N protein
Bead #30
BTV VP7
Number of 
positive sera
Positive serum 
samples
RVFV experimental 
sera
0 2 0 6 50
SBV experimental 
sera
0 2 16 27 74
TB experimental 
sera
0 0 0 0 26
CCHFV field 
positive
0 16 11 19 30
BTV experimental 
sera
0 1 20 12 88
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Finally, this multiplex assay is advantageous as it allows saving 
time and sample volume, as 96 samples can be analysed against 
five diseases in 4 hr, using only 0.5 μL of serum, versus 144 μl of 
serum that would be required to perform the five independent 
ELISAs used as references. Moreover, it is a flexible, open system 
that will allow including target antigens from other pathogens of 
interest (such as epizootic hemorrhagic disease or peste des petits 
ruminants), to broaden the range and impact of this assay.
This five-plex assay could be used as a screening tool, to assess 
the presence and prevalence of antibodies against these five highly 
pathogenic agents and identify regions at risk of infection. This in-
formation will help to minimize the spread and further transmission 
of those pathogens within the human population.
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